Found: 66
Select item for more details and to access through your institution.
Risk of progression in chronic phase‐chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR‐PRO study.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 11, p. 1762, doi. 10.1002/ajh.27073
- By:
- Publication type:
- Article
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 8, p. E296, doi. 10.1002/ajh.26618
- By:
- Publication type:
- Article
Age and d PCR can predict relapse in CML patients who discontinued imatinib: The ISAV study.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 10, p. 910, doi. 10.1002/ajh.24120
- By:
- Publication type:
- Article
Imatinib in Philadelphia chromosome-positive chronic phase CML patients: Molecular and cytogenetic response rates and prediction of clinical outcome.
- Published in:
- American Journal of Hematology, 2003, v. 73, n. 4, p. 249, doi. 10.1002/ajh.10364
- By:
- Publication type:
- Article
Variable Outcomes of Hepatitis E Infections in Patients with Hemato-Oncologic Diseases.
- Published in:
- Oncology Research & Treatment, 2023, v. 46, n. 7/8, p. 296, doi. 10.1159/000531538
- By:
- Publication type:
- Article
Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management.
- Published in:
- Acta Haematologica, 2020, v. 143, n. 3, p. 217, doi. 10.1159/000501927
- By:
- Publication type:
- Article
Longitudinal Study to Assess the Clinical Significance of MSI2 Expression in Chronic Myeloid Leukemia Patients.
- Published in:
- Acta Haematologica, 2016, v. 136, n. 1, p. 62, doi. 10.1159/000445097
- By:
- Publication type:
- Article
BCR-ABL1 Acute Myeloid Leukemia: Clonal Selection of a BCR-ABL1<sup>-</sup> Subclone as a Cause of Refractory Disease with Nilotinib Treatment.
- Published in:
- Acta Haematologica, 2015, v. 133, n. 2, p. 237, doi. 10.1159/000368176
- By:
- Publication type:
- Article
Effects of Jak2 Type 1 Inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 Mutation-Positive and Bcr-Abl-Positive Cell Lines.
- Published in:
- Acta Haematologica, 2014, v. 132, n. 1, p. 75, doi. 10.1159/000356784
- By:
- Publication type:
- Article
Emerging Role of Tyrosine Kinases as Drugable Targets in Cancer.
- Published in:
- Biomarker Insights, 2015, v. 10, p. 29, doi. 10.4137/BMI.S22432
- By:
- Publication type:
- Article
Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia.
- Published in:
- Applied Health Economics & Health Policy, 2019, v. 17, n. 4, p. 555, doi. 10.1007/s40258-019-00489-0
- By:
- Publication type:
- Article
Adjuvant chemotherapy with folinic acid and 5-fluorouracil in patients with locally advanced rectal cancer previously treated by preoperative radiochemotherapy and curative tumor resection.
- Published in:
- International Journal of Colorectal Disease, 2006, v. 21, n. 6, p. 582, doi. 10.1007/s00384-005-0054-9
- By:
- Publication type:
- Article
Severe peripheral arterial disease during nilotinib therapy.
- Published in:
- 2011
- By:
- Publication type:
- letter
Severe Peripheral Arterial Disease During Nilotinib Therapy.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2011, v. 103, n. 17, p. 1347, doi. 10.1093/jnci/djr292
- By:
- Publication type:
- Article
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2011, v. 103, n. 7, p. 553, doi. 10.1093/jnci/djr060
- By:
- Publication type:
- Article
Nilotinib: A Viewpoint by Philipp le Coutre.
- Published in:
- Drugs, 2008, v. 68, n. 4, p. 460, doi. 10.2165/00003495-200868040-00007
- By:
- Publication type:
- Article
CML-413: Asciminib Provides Durable Responses and a Favorable Safety Profile in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with the T315I Mutation in a Phase 1 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S335, doi. 10.1016/S2152-2650(21)01784-5
- By:
- Publication type:
- Article
CML-081: Effect of Comorbidities on Response Outcomes with First-Line Tyrosine Kinase Inhibitors (TKIs), Dasatinib Versus Imatinib, in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Post Hoc Analysis of DASISION.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S326, doi. 10.1016/S2152-2650(21)01766-3
- By:
- Publication type:
- Article
Poster: CML-413: Asciminib Provides Durable Responses and a Favorable Safety Profile in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with the T315I Mutation in a Phase 1 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S224, doi. 10.1016/S2152-2650(21)01409-9
- By:
- Publication type:
- Article
Poster: CML-081: Effect of Comorbidities on Response Outcomes With First-Line Tyrosine Kinase Inhibitors (TKIs), Dasatinib Versus Imatinib, in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Post Hoc Analysis of DASISION.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S223, doi. 10.1016/S2152-2650(21)01406-3
- By:
- Publication type:
- Article
Combination of Asciminib+Nilotinib or Asciminib+Dasatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S290, doi. 10.1016/j.clml.2019.07.236
- By:
- Publication type:
- Article
Efficacy and Safety of Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor Targeting the Myristoyl-Binding Site, in Patients with Chronic Myeloid Leukemia (CML) Carrying the T315I Mutation.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S289, doi. 10.1016/j.clml.2019.07.234
- By:
- Publication type:
- Article
Treatment-Free Remission (TFR) Following Frontline Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 192-Weeks Data from the ENESTfreedom Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S288, doi. 10.1016/j.clml.2019.07.232
- By:
- Publication type:
- Article
Combination of Asciminib, a Novel and Specific BCR-ABL1 Inhibitor, Plus Imatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S287, doi. 10.1016/j.clml.2019.07.231
- By:
- Publication type:
- Article
ENESTfreedom 144-Week Update: Long-Term Treatment-Free Remission (TFR) Following Frontline Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S226, doi. 10.1016/j.clml.2018.07.099
- By:
- Publication type:
- Article
5-Year Updates from the Pivotal Phase 2 Ponatinib PACE Trial: Efficacy, Safety and Landmark Analysis in Heavily Pretreated Patients with Chronic-Phase Chronic Myeloid Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S307, doi. 10.1016/j.clml.2017.07.105
- By:
- Publication type:
- Article
4-Year Results from the Pivotal Phase 2 PACE Trial: Efficacy and Safety in Heavily Pretreated Leukemia Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S56, doi. 10.1016/j.clml.2016.07.082
- By:
- Publication type:
- Article
Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2004, v. 53, n. 4, p. 313, doi. 10.1007/s00280-003-0741-6
- By:
- Publication type:
- Article
Early molecular response in East African Philadelphia chromosome-positive chronic myeloid leukaemia patients treated with Imatinib and barriers to access treatment.
- Published in:
- Ecancermedicalscience, 2020, v. 14, n. 1063-1111, p. 1, doi. 10.3332/ecancer.2020.1089
- By:
- Publication type:
- Article
Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia.
- Published in:
- British Journal of Haematology, 2007, v. 137, n. 4, p. 297, doi. 10.1111/j.1365-2141.2007.06547.x
- By:
- Publication type:
- Article
Simultaneous cytokine analysis by cytometric bead array for the detection of leukaemia-reactive T cells in patients with chronic myeloid leukaemia.
- Published in:
- British Journal of Haematology, 2006, v. 132, n. 1, p. 32, doi. 10.1111/j.1365-2141.2005.05844.x
- By:
- Publication type:
- Article
research paper Filgrastim-induced stem cell mobilization in chronic myeloid leukaemia patients during imatinib therapy: safety, feasibility and evidence for an efficient in vivo purging.
- Published in:
- British Journal of Haematology, 2004, v. 124, n. 2, p. 195, doi. 10.1046/j.1365-2141.2003.04756.x
- By:
- Publication type:
- Article
Fluorescent 5′-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: implications for monitoring human leukaemias.
- Published in:
- British Journal of Haematology, 2001, v. 114, n. 2, p. 313, doi. 10.1046/j.1365-2141.2001.02912.x
- By:
- Publication type:
- Article
Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2019, v. 145, n. 6, p. 1589, doi. 10.1007/s00432-019-02894-3
- By:
- Publication type:
- Article
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2018, v. 144, n. 5, p. 945, doi. 10.1007/s00432-018-2604-x
- By:
- Publication type:
- Article
Long‐term observation of the frequency of secondary colorectal cancer and other malignancies in tyrosine kinase inhibitor treated chronic myeloid leukemia patients and controls.
- Published in:
- EJHaem, 2022, v. 3, n. 3, p. 949, doi. 10.1002/jha2.502
- By:
- Publication type:
- Article
HLA class I-restricted T cell epitopes isolated and identified from myeloid leukemia cells.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1038/s41598-019-50341-7
- By:
- Publication type:
- Article
Anxieties, age and motivation influence physical activity in patients with myeloproliferative neoplasms - a multicenter survey from the East German study group for hematology and oncology (OSHO #97).
- Published in:
- Frontiers in Oncology, 2023, v. 12, p. 1, doi. 10.3389/fonc.2022.1056786
- By:
- Publication type:
- Article
A modified EBMT risk score predicts the outcome of patients with acute myeloid leukemia receiving allogeneic stem cell transplants.
- Published in:
- European Journal of Haematology, 2011, v. 86, n. 4, p. 305, doi. 10.1111/j.1600-0609.2011.01580.x
- By:
- Publication type:
- Article
BCR-ABL positive cells and chronic myeloid leukemia in immune suppressed organ transplant recipients.
- Published in:
- European Journal of Haematology, 2010, v. 84, n. 1, p. 26, doi. 10.1111/j.1600-0609.2009.01357.x
- By:
- Publication type:
- Article
Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment.
- Published in:
- European Journal of Haematology, 2003, v. 70, n. 4, p. 231, doi. 10.1034/j.1600-0609.2003.00044.x
- By:
- Publication type:
- Article
Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia.
- Published in:
- European Journal of Haematology, 2002, v. 69, n. 4, p. 254, doi. 10.1034/j.1600-0609.2002.02830.x
- By:
- Publication type:
- Article
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.
- Published in:
- Journal of Hematology & Oncology, 2021, v. 14, n. 1, p. 1, doi. 10.1186/s13045-020-01004-y
- By:
- Publication type:
- Article
Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Expanding Nilotinib Access in Clinical Trials (ENACT).
- Published in:
- Cancer (0008543X), 2012, v. 118, n. 1, p. 118, doi. 10.1002/cncr.26249
- By:
- Publication type:
- Article
Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Activity and Tolerability of Nilotinib.
- Published in:
- Cancer (0008543X), 2010, v. 116, n. 19, p. 4564, doi. 10.1002/cncr.25351
- By:
- Publication type:
- Article
Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2013, v. 139, n. 12, p. 1985, doi. 10.1007/s00432-013-1529-7
- By:
- Publication type:
- Article